alexnader Kutikov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3950175/publications.pdf

Version: 2024-02-01

108046 71088 7,075 165 37 80 citations h-index g-index papers 165 165 165 6538 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Management of SHDB positive patient with metastatic bilateral giant retroperitoneal paragangliomas. Urology Case Reports, 2022, 40, 101950.	0.1	1
2	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	0.5	12
3	A Point-of-Care Resource to Improve Care of Patients with Adrenal Mass: www.AdrenalMass.org. European Urology, 2022, 81, 434.	0.9	1
4	Propensity-score matched oncological outcomes and patterns of recurrence following open and minimally-invasive partial nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 111.e19-111.e25.	0.8	2
5	Ischemia Time Has Little Influence on Renal Function Following Partial Nephrectomy: Is It Time for Urology to Stop the Tick-Tock Dance?. European Urology, 2022, 81, 501-502.	0.9	10
6	Predictive Models for Patients with a Renal Mass in the Clinical Trenches Continue to be a Muddy Proposition. European Urology, 2022, , .	0.9	4
7	Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology. European Urology, 2022, , .	0.9	11
8	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. European Urology, 2022, 81, 476-488.	0.9	44
9	The Delayed Nephrogram: Point-of-care Quantitative Measurement, Validation as an Indicator of Obstruction, and Novel Use as a Predictor of Renal Functional Impairment. European Urology Focus, 2022, 8, 1809-1815.	1.6	1
10	The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis. Journal of Urology, 2022, 208, 71-79.	0.2	24
11	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	1.3	9
12	Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma. European Urology, 2022, 81, 317-318.	0.9	3
13	Redefining the Gender Gap in Urology Authorship: An 18-Year Publication Analysis. European Urology Focus, 2022, 8, 1512-1519.	1.6	7
14	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq0 0 0 rgI	BT #Qoverlo	ck 1 0 Tf 50 21
15	Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041. European Urology, 2022, 82, e12-e12.	0.9	0
16	Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. European Journal of Cancer, 2022, 168, 68-76.	1.3	0
17	A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board Membership. European Urology Focus, 2022, 8, 1751-1757.	1.6	6
18	Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic. Urology, 2021, 147, 50-56.	0.5	12

#	Article	IF	CITATIONS
19	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. European Urology, 2021, 80, 575-588.	0.9	48
20	Improved cancer coping from a webâ€based intervention for prostate cancer survivors: A randomized controlled trial. Psycho-Oncology, 2021, 30, 1466-1475.	1.0	11
21	Safety of neoadjuvant chemotherapy in patients with muscleâ€invasive bladder cancer and malignant ureteric obstruction. BJU International, 2021, , .	1.3	1
22	The future of "Retro―robotic partial nephrectomy. Translational Andrology and Urology, 2021, 10, 2199-2208.	0.6	4
23	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pTO Bladder Cancer: A Prospective Trial. Journal of Urology, 2021, 205, 1605-1611.	0.2	11
24	Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e9-790.e15.	0.8	4
25	Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 1467.	3.4	14
26	Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e1-791.e7.	0.8	5
27	Don't SPARE me: details matter!. BJU International, 2021, 128, 525-526.	1.3	0
28	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	2.0	11
29	Growth of the Twitter Presence of Academic Urology Training Programs and Its Catalysis by the COVID-19 Pandemic. European Urology, 2021, 80, 261-263.	0.9	11
30	Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors. Urology, 2021, 158, 125-130.	0.5	1
31	Multiple brain metastases in a patient with ypTONO micropapillary urothelial carcinoma of the bladder. Urology Case Reports, 2021, 39, 101838.	0.1	2
32	Harnessing choice architecture in urologic practice: Implementation of an opioid-sparing protocol grounded in cognitive behavioral theory. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 95-95.	0.8	0
33	The Association of Robot-assisted Versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. European Urology Focus, 2020, 6, 305-312.	1.6	20
34	Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Survey. European Urology Focus, 2020, 6, 273-279.	1.6	8
35	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European Urology Oncology, 2020, 3, 104-111.	2.6	11
36	Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 56-61.	0.9	4

#	Article	IF	CITATIONS
37	Neoadjuvant checkpoint inhibition in renal cell carcinoma associated Stauffer's syndrome. Urology Case Reports, 2020, 29, 101077.	0.1	4
38	Predictive Value of Nephrometry Scores in Nephron-sparing Surgery: A Systematic Review and Meta-analysis. European Urology Focus, 2020, 6, 490-504.	1.6	63
39	Controversies in management of the bladder cuff at nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1868-1880.	0.6	12
40	A leopard never changes its spots: Development of colonic adenocarcinoma in an Indiana Pouch. Urology Case Reports, 2020, 33, 101396.	0.1	0
41	Pathologically Node-Positive Prostate Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 58-63.	1.0	1
42	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T ₂₋₄ Renal Masses. Journal of Endourology, 2020, 34, 289-297.	1.1	9
43	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity scoreâ€matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU International, 2020, 126, 114-123.	1.3	42
44	Refractory hypertension due to unilateral renal lymphangiectasia: An uncommon case with a surgical solution. Urology Case Reports, 2020, 32, 101177.	0.1	4
45	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.2	61
46	Role of minimally invasive partial nephrectomy in the management of renal mass. Translational Andrology and Urology, 2020, 9, 3140-3148.	0.6	7
47	Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 389-407.	3.9	26
48	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.2	1
49	Bacillus Calmette-Guérin Packaged for Percutaneous Vaccination Can Be Safely Used for Intravesical Instillation in Patients with Urothelial Carcinoma of the Bladder. Urology Practice, 2020, 7, 487-489.	0.2	0
50	Is Knowledge Power or Is Ignorance Bliss: Screening and Management of Familial Renal Cell Carcinoma Syndromes. European Urology, 2019, 76, 765-766.	0.9	0
51	Modern Management of Kidney Cancer: Is a Chance to Cut a Chance to Cure?. European Urology Focus, 2019, 5, 921-922.	1.6	0
52	A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World Journal of Urology, 2019, 37, 2099-2108.	1.2	4
53	Spontaneous resolution of a 10 cm heterogenous renal lesion upon expectant management. Urology Case Reports, 2019, 23, 85-86.	0.1	0

Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq0 0 0 rgBT /2 verlock 136 Tf 50 62

#	Article	IF	CITATIONS
55	Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes. European Urology, 2019, 75, 477-491.	0.9	65
56	Renal Hilar Lesions: Biological Implications for Complex Partial Nephrectomy. Urology, 2019, 123, 174-180.	0.5	17
57	The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 3-10.	0.9	3
58	The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death and Disease, 2018, 9, 374.	2.7	35
59	Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of Biophotonics, 2018, 11, e201700188.	1.1	33
60	Treatment Trends and Outcomes for Patients With Lymph Node–Positive Cancer of the Penis. JAMA Oncology, 2018, 4, 643.	3.4	54
61	Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines. Journal of Urology, 2018, 199, 906-914.	0.2	22
62	Editorial Comment. Journal of Urology, 2018, 199, 639-640.	0.2	0
63	Differences in Survival Associated with Performance of Lymph Node Dissection inÂPatients with Invasive Penile Cancer: Results from the National Cancer Database. Journal of Urology, 2018, 199, 1238-1244.	0.2	24
64	External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy. Journal of Urology, 2018, 199, 649-654.	0.2	17
65	Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 193-212.	0.8	1
66	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Journal of Urology, 2018, 199, 969-975.	0.2	5
67	Safeguarding the Future of Urological Research and Delivery of Clinical Excellence by Harnessing the Power of Youth to Spearhead Urological Research. European Urology, 2018, 73, 645-647.	0.9	5
68	Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy. Kidney Cancer, 2018, 2, 47-55.	0.2	1
69	Robotic Inferior Vena Cava Thrombectomy: Are We Entering the House Through an Attic Window?. European Urology Focus, 2018, 4, 641-642.	1.6	6
70	The Alphabet Soup of Modern Nephrometry Systems. European Urology Oncology, 2018, 1, 435-436.	2.6	2
71	Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ibâ€II renal masses: An analysis of the national cancer data base. Cancer, 2018, 124, 3839-3848.	2.0	37
72	Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	0.9	53

#	Article	IF	CITATIONS
73	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). European Urology, 2018, 74, 226-232.	0.9	109
74	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Molecular Cancer Therapeutics, 2018, 17, 1355-1364.	1.9	280
75	Functional Parenchymal Volume-based Spectrum Score Is Able to Quantify Ischemic Injury After Partial Nephrectomy. Urology, 2018, 120, 150-155.	0.5	5
76	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. European Urology, 2018, 74, 387-393.	0.9	41
77	Role of Active Surveillance for Localized Small Renal Masses. European Urology Oncology, 2018, 1, 177-187.	2.6	85
78	Editorial Comment. Urology, 2017, 102, 136-137.	0.5	2
79	Editorial Comment. Journal of Urology, 2017, 197, 383-384.	0.2	1
80	Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. Urology Practice, 2017, 4, 349-354.	0.2	2
81	The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 153.e15-153.e20.	0.8	39
82	Update on Renal Mass Biopsy. Current Urology Reports, 2017, 18, 28.	1.0	14
83	LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. British Journal of Cancer, 2017, 116, 1203-1207.	2.9	25
84	Current Role of Renal Biopsy in Urologic Practice. Urologic Clinics of North America, 2017, 44, 203-211.	0.8	11
85	The Small Renal Mass and Its Management in Urologic Practice. Urologic Clinics of North America, 2017, 44, xvii.	0.8	2
86	Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach. Urology Case Reports, 2017, 10, 38-41.	0.1	9
87	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. European Urology, 2017, 72, 64-75.	0.9	91
88	Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nature Reviews Urology, 2017, 14, 669-682.	1.9	34
89	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 665-669.	0.8	0
90	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladderâ€preservation therapy for muscleâ€invasive bladder cancer. Cancer, 2017, 123, 4337-4345.	2.0	72

#	Article	IF	CITATIONS
91	Resolution of a Debilitating Paraneoplastic Parkinson-like Neurological Syndrome Following Tyrosine Inhibitor Therapy and Consolidative Nephrectomy in a Patient with Advanced Clear Cell Renal CellÂCarcinoma. Urology Case Reports, 2017, 14, 18-20.	0.1	4
92	Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e17-662.e21.	0.8	13
93	Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 670.e15-670.e21.	0.8	16
94	Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. European Urology, 2017, 71, 495.	0.9	0
95	Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. Journal of Urology, 2017, 197, 31-36.	0.2	14
96	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clinical Genitourinary Cancer, 2017, 15, e337-e343.	0.9	18
97	Understanding Mutational Drivers of Risk: An Important Step Toward Personalized Care for Patients with Renal Cell Carcinoma. European Urology Focus, 2017, 3, 428-429.	1.6	3
98	Reply to Patrick O. Richard, Micheal A.S. Jewett and Antonio Finelli's Letter to the Editor re: Alexander Kutikov, Marc C. Smaldone, Robert G. Uzzo, Miki Haifler, Gennady Bratslavsky, Bradley C. Leibovich. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016;70:403–6. European Urology, 2017, 71, e47-e48.	0.9	3
99	Surveillance of Small Renal Masses in Young Patients: A Viable Option in the Appropriate Candidate. European Urology Focus, 2016, 2, 567-568.	1.6	6
100	Harnessing Proteinuria as a Predictor of Postsurgical Outcomes in Kidney Cancer Patients. European Urology Focus, 2016, 2, 623-624.	1.6	1
101	Renal Mass Biopsy: Always, Sometimes, or Never?. European Urology, 2016, 70, 403-406.	0.9	80
102	Telemedicine in Urology: State of the Art. Urology, 2016, 94, 10-16.	0.5	74
103	Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e9-486.e15.	0.8	12
104	Biology is Destiny: A Case of Adrenocortical Carcinoma Diagnosed and Resected at Inception in a Patient Under Close Surveillance for Lung Cancer. Urology Case Reports, 2016, 9, 9-11.	0.1	0
105	Editorial Comment. Journal of Urology, 2016, 196, 1355-1355.	0.2	1
106	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	1.3	32
107	Active Surveillance for Small Renal Masses: When Less is More. European Urology Focus, 2016, 2, 660-668.	1.6	31
108	Ureteral Involvement Within an Incarcerated Inguinal Hernia in a Patient With Crossed-fused Renal Ectopia. Urology Case Reports, 2016, 7, 20-22.	0.1	2

#	Article	IF	Citations
109	Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. European Urology, 2016, 69, 183-185.	0.9	38
110	Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World Journal of Urology, 2016, 34, 687-693.	1.2	24
111	Papillary Thyroid Carcinoma Metastases Presenting as Ipsilateral Adrenal Mass and Renal Cyst. Urology Case Reports, 2015, 3, 221-222.	0.1	7
112	Impact of obesity on outcomes after definitive doseâ€escalated intensityâ€modulated radiotherapy for localized prostate cancer. Cancer, 2015, 121, 3010-3017.	2.0	40
113	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU International, 2015, 116, 351-357.	1.3	29
114	Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 525-530.	2.3	1
115	Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma. Urology, 2015, 86, 1165-1173.	0.5	8
116	Some Renal Masses Did Not "Read the Book― A Case of a High Grade Hybrid Renal Tumor Masquerading as a Renal Cyst on Non-contrast Imaging. Urology Case Reports, 2015, 3, 219-220.	0.1	5
117	Focal Therapy for Treatment of the Small Renal Mass: Dealer's Choice or a Therapeutic Gamble?. European Urology, 2015, 67, 260-261.	0.9	13
118	Retrospective Comparison of Cardiovascular Risk in Preselected Patients Undergoing Kidney Cancer Surgery: Reflection of Reality or Simply What We Want to Hear?. European Urology, 2015, 67, 690-691.	0.9	10
119	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.2	32
120	Reply to Vincenzo Ficarra, Vito Palumbo, Afrovita Kungulli and Gianluca Giannarini's Letter to the Editor re: Andrea Minervini, Marco Carini, Robert G. Uzzo, Riccardo Campi, Marc C. Smaldone, Alexander Kutikov. Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface–Intermediate–Base Margin Score. Eur Urol 2014;66:803–5. European Urology, 2015, 67,	0.9	2
121	e48-e51. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry, 2015, 40, 186-189.	0.4	5
122	Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. European Urology, 2015, 68, 61-74.	0.9	274
123	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. Clinical Genitourinary Cancer, 2015, 13, 142-149.	0.9	7
124	Understanding Chronic Kidney Disease of Surgical Versus Medical Origin: The Missing Link to the Partial Versus Radical Nephrectomy Debate?. European Urology, 2015, 68, 1004-1006.	0.9	7
125	Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Practical Radiation Oncology, 2015, 5, e215-e222.	1.1	21
126	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. European Urology, 2015, 68, 980-992.	0.9	206

#	Article	IF	Citations
127	Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e7-167.e12.	0.8	26
128	Small renal mass management in the elderly and the calibration of risk. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 197-200.	0.8	12
129	Indications, Techniques, Outcomes, and Limitations for Minimally Ischemic and Off-clamp Partial Nephrectomy: A Systematic Review of the Literature. European Urology, 2015, 68, 632-640.	0.9	127
130	Histopathological Validation of the Surface-Intermediate-Base Margin Score for Standardized Reporting of Resection Technique during Nephron Sparing Surgery. Journal of Urology, 2015, 194, 916-922.	0.2	25
131	Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e19-388.e25.	0.8	36
132	Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy. Urology, 2015, 86, 300-306.	0.5	64
133	Reply. Urology, 2015, 86, 306.	0.5	О
134	Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. European Urology, 2015, 67, 85-97.	0.9	403
135	Growth Kinetics and Short-Term Outcomes of cT1b and cT2 Renal Masses under Active Surveillance. Journal of Urology, 2014, 192, 659-664.	0.2	70
136	Care Transitions between Hospitals are Associated with Treatment Delay for Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 1349-1354.	0.2	33
137	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e9-47.e14.	0.8	55
138	Renal Pelvic Anatomy Is Associated with Incidence, Grade, and Need for Intervention for Urine Leak Following Partial Nephrectomy. European Urology, 2014, 66, 949-955.	0.9	32
139	Is Extended Pharmacologic Venous Thromboembolism Prophylaxis Uniformly Safe After Radical Cystectomy?. Urology, 2014, 84, 1152-1156.	0.5	12
140	Reply. Urology, 2014, 84, 1156.	0.5	0
141	Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface–Intermediate–Base Margin Score. European Urology, 2014, 66, 803-805.	0.9	86
142	Internal Validation of the Renal Pelvic Score: A Novel Marker of Renal Pelvic Anatomy That Predicts Urine Leak After Partial Nephrectomy. Urology, 2014, 84, 351-357.	0.5	26
143	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	0.9	72
144	Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. Journal of Urology, 2014, 191, 296-300.	0.2	49

#	Article	IF	Citations
145	Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents. European Urology, 2014, 66, 118-119.	0.9	40
146	Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology, 2014, 32, 1895-1901.	0.8	241
147	Patients with anatomically "simple―renal masses are more likely to be placed on active surveillance than those with anatomically "complex―lesions. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1267-1271.	0.8	13
148	Anatomic Complexity Quantitated by Nephrometry Score Is Associated With Prolonged Warm Ischemia Time During Robotic Partial Nephrectomy. Urology, 2014, 84, 340-344.	0.5	27
149	Splenogonadal Fusion: A Rare Etiology of Solid Testicular Mass. Urology, 2014, 83, e1-e2.	0.5	22
150	Assessing the Burden of Complications After Surgery for Clinically Localized Kidney Cancer by Age and Comorbidity Status. Urology, 2014, 83, 843-850.	0.5	63
151	Competing Risks of Death in Patients with Localized Renal Cell Carcinoma: A Comorbidity Based Model. Journal of Urology, 2012, 188, 2077-2083.	0.2	108
152	Academic Ranking Score: A Publication-Based Reproducible Metric of Thought Leadership in Urology. European Urology, 2012, 61, 435-439.	0.9	13
153	Routine Adrenalectomy Is Unnecessary During Surgery for Large and/or Upper Pole Renal Tumors When the Adrenal Gland Is Radiographically Normal. Journal of Urology, 2011, 185, 1198-1203.	0.2	21
154	The Gatekeeper Disparity—Why Do Some Medical Schools Send More Medical Students Into Urology?. Journal of Urology, 2011, 185, 647-652.	0.2	35
155	Effects of Increased Cross-Sectional Imaging on the Diagnosis and Prognosis of Adrenocortical Carcinoma: Analysis of the National Cancer Database. Journal of Urology, 2011, 186, 805-810.	0.2	22
156	Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-resistant Prostate Cancer. Urology, 2011, 78, 968.e7-968.e11.	0.5	21
157	Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score. European Urology, 2011, 60, 241-248.	0.9	233
158	Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU International, 2010, 106, 218-223.	1.3	60
159	Reply to J. Lagro et al and G. Lughezzani et al. Journal of Clinical Oncology, 2010, 28, e301-e301.	0.8	2
160	Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram. Journal of Clinical Oncology, 2010, 28, 311-317.	0.8	265
161	The Impact of Residency Match Information Disseminated by a Third-Party Website. Journal of Surgical Education, 2009, 66, 212-215.	1.2	12
162	The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth. Journal of Urology, 2009, 182, 844-853.	0.2	1,886

ALEXNADER KUTIKOV

#	Article	IF	CITATIONS
163	Focal therapy for kidney cancer: a systematic review. Current Opinion in Urology, 2009, 19, 148-153.	0.9	38
164	Twitter Footprint and the Match in the COVID-19 Era: Understanding the Relationship Between Applicant Online Activity and Residency Match Success. Urology Practice, $0, , .$	0.2	0
165	Oncological Outcomes of cT1 and cT2 Micropapillary Variant Compared With cT1 and cT2 Conventional Urothelial Carcinoma Treated With Radical Cystectomy. Urology Practice, 0, , .	0.2	O